Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (3 quarters reported)
$107M in Q4 2025 → $104M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Revolution Medicines Inc | 54.5% | Trimmed 63% | 303,133 | $56.8M |
| Oric Pharmaceuticals Inc | 39.8% | Added 56% | 3,828,460 | $41.5M |
| Novabridge Biosciences | 5.4% | Added 27% | 2,878,033 | $5.61M |
| Korro Bio Inc | 0.4% | Unchanged | 30,265 | $399K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 2 quarters.
quarter ended June 30, 2026 · filed August 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Revolution Medicines Inc | Trimmed | −525,841 | −$98.5M | 54.5% |
| Oric Pharmaceuticals Inc | Added | +1,368,909 | +$14.8M | 39.8% |
| Cogent Biosciences Inc | Exited | −51,402 | −$1.98M | — |
| Novabridge Biosciences | Added | +615,100 | +$1.2M | 5.4% |
quarter ended March 31, 2026 · filed May 08, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Oric Pharmaceuticals Inc | New | +2,459,551 | +$31.2M | 26.0% |
| Protagonist Therapeutics Inc | Exited | −189,823 | −$16.6M | — |
| Arrivent Biopharma Inc | Exited | −644,788 | −$13M | — |
| Revolution Medicines Inc | Trimmed | −71,418 | −$6.95M | 67.4% |
| Novabridge Biosciences | Added | +1,848,954 | +$4.55M | 4.7% |
| Cogent Biosciences Inc | Trimmed | −48,598 | −$1.87M | 1.7% |
Loading...
